Plain-English translation of NCT05056844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new imaging technique called contrast-enhanced spectral mammography (CESM) to help doctors find the cause of abnormal nipple discharge. The scan uses a special dye injected into your vein to help show breast tissue more clearly. Researchers want to see if this new scan is better at detecting breast conditions than standard imaging tests.
Abnormal nipple discharge can be a sign of breast cancer or other serious conditions, but doctors sometimes have trouble figuring out exactly what's causing it with standard imaging. This trial exists to find out whether the new imaging technique can help doctors spot the problem more reliably and avoid unnecessary biopsies.
You likely qualify if…
You likely don't qualify if…
You will receive an IV injection of contrast dye, then undergo a special imaging scan called CESM that takes 10–15 minutes. You may also have a standard digital mammogram and breast ultrasound if you haven't had them recently. Researchers will follow your results to see if the new scan helped doctors identify the cause of your nipple discharge and guide any necessary next steps.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~66 participants
Started
April 2021
Primary completion
April 2027
Age range
25 Years – 85 Years
Sex
Female only
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Olena Weaver, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.